AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

AN2 Therapeutics, Inc.NASDAQ: ANTX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$10.03M, compared with -$10.65M a year earlier. Trailing-twelve-month EBITDA was -$35.85M.

Context

  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -1188.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.03M-0.2% QoQ
Last fiscal yearDec 2025
-$35.17M-1188.0% YoY
LTMMar 2026
-$35.85M-213.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%+100.0%+94.2 pp
1 year-1188.0%+100.0%+1288.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(35.17M) USD
Year-over-year change
-1188.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ANTX compares with its peers on the latest reported figures

  • ANTX's LTM Mar 2026 EBITDA of -$35.85M is the 5th highest of the 6 companies compared; the peer median is -$11.36M.
  • Its year-over-year change of -213.1% is the lowest of 6, against a peer median of +71.7%.
ANTX Competitors Peer median
EBITDA for ANTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M +154.8%—41.2%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$9.46M +71.7%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-$11.36M +79.6%—30.6%
IBIOiBio, Inc.LTM Jun 2026-$32.35M -89.8%—32345.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$35.85M -213.1%——
BOLDBoundless Bio, Inc.LTM Mar 2026-$54.78M +15.1%——
Peer median (excluding ANTX) -$11.36M+71.7%—41.2%

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue077K000
Gross Profit0(77K)000
Gross Margin—————
Research & Development16.91M29.51M54.87M40.49M24.77M
Selling, General & Admin4.67M12.75M14.76M14.07M13.34M
Operating Expenses21.57M42.19M69.64M54.55M38.11M
Depreciation & Amortization077K69.64M54.55M0
EBITDA(21.54M)(40.88M)4.9M3.23M(35.17M)
EBITDA Margin—————
Operating Income(21.57M)(42.26M)(69.64M)(54.55M)(38.11M)
Operating Margin—————
Interest Income69K1.35M4.86M5.47M2.93M
Interest Expense0514K000
Other Income / Expenses31K1.31M4.9M3.23M2.94M
Income Before Tax(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Net Margin—————
EPS (Basic)(1.50)(2.79)(2.74)(1.72)(1.16)
EPS (Diluted)(1.50)(2.79)(2.74)(1.72)(1.16)
Weighted Avg Shares18.74M15.34M23.6M29.83M30.22M
Weighted Avg Shares (Diluted)18.74M15.34M23.6M29.83M30.22M

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.